Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04868253
Status:
UNKNOWN
Last Update Posted:
2021-05-28
First Post:
2020-10-05
Brief Title:
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
Sponsor:
Rose Research Center LLC
Organization:
Rose Research Center LLC
Study Overview
Official Title:
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label study will evaluate EMB-001 comprised of metyrapone a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal HPA axis function combined with oxazepam an anxiolytic and sedativehypnotic benzodiazepine to help smokers abstain from smoking during a 12-week trial period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None